Skip to content

Search

Showing results for "mental health aboriginal"

The Kids Research Institute Australia shares in new infrastructure funding

The Telethon Kids Institute welcomes the State Government's new $1.2 million funding initiative to support WA's research institutes.

Reproduction in females: the role of the early life environment

There is now compelling evidence that long-term health and physiological function are modified by events that occur early in life and involve interactions...

Type 2 Diabetes in Indigenous Australian children

Rates of type 2 diabetes are higher among Indigenous than non-Indigenous Australian children and adolescents.

Jenny Mountain

Jenny Mountain is a Program Manager in the Neonatal Health team at The Kids Research Institute Australia.

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021

Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. 

A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)

Pneumococcal disease (PD) remains a major health concern globally. In children, pneumococcal conjugate vaccines (PCVs) provide protection against PD from most vaccine serotypes, but non-vaccine serotypes contribute to residual disease. V114 is a 15-valent PCV containing all 13 serotypes in Prevnar 13™ and public health important serotypes 22F and 33F. This phase 3 study evaluated safety and immunogenicity of mixed PCV13/V114 regimens using a 3 + 1 dosing schedule when changing from PCV13 to V114 at doses 2, 3, or 4.